EU OKs Mundipharma’s Neulasta biosimilar
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
Read More
Tag: Neulasta
US OKs first biosimilar of Amgen’s Neulasta
Mylan and Biocon’s Fulphila has become the first biosimilar of Amgen’s Neulasta to be approved by the US Food and Drug Administration.
Read More
Gedeon’s re-filed Neulasta biosimilar under EU review
European regulators have accepted a resubmission of Gedeon Richter’s biosimilar to Amgen’s Neulasta.
Read More
EU regulators to review Sandoz’ Neulasta biosimilar
The European Medicines Agency has accepted for review Novartis unit Sandoz’ biosimilar of Amgen’s Neulasta.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
